Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Gastric Cancer | Research

GRB7 plays a promoting role in the progression of gastric cancer

Authors: Guomin Zhu, Hu Cai, Qiang Xiao, Shukun Zeng, Xiaohua Jiang, Donglan Liu

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Gastric cancer is a clinically common tumor, showing an upward trend of both incidence and mortality. GRB7 has been identified as a vital regulator in tumor progression. This study aims to uncover the biological function of GRB7 in gastric cancer process.

Methods

immunohistochemical (IHC) staining using a tissue microarray (TMA), quantitative reverse transcription PCR (qRT-PCR) and Western blotting were performed to detect the expression of genes. Furthermore, gastric cancer cell lines AGS and MGC-803 were transfected with short hairpin RNAs against GRB7. The biological function of GRB7 in gastric cancer cells were examined by CCK-8, flow cytometry, wound healing and Transwell assays. Then, in vivo tumor formation assay was conducted to explore the effects of GRB7 on tumor growth. Finally, expression levels of proteins related to cell functions were determined by Western blotting. Coimmunoprecipitation (CoIP) assay was performed to assess the protein-protein interaction.

Results

GRB7 was up-regulated in gastric cancer tissues and cell lines, and its expression was inversely proportional to survival of gastric cancer patients. Moreover, GRB7 knockdown inhibited proliferative, migratory abilities, as well as promoted cell apoptosis in gastric cancer cells. Further study suggested that GRB7 silencing could suppress gastric cancer tumor growth in vivo. Furthermore, our study uncovered an important interaction between GRB7 and MyD88. Silencing MyD88 was observed to alleviate the malignant phenotypes promoted by GRB7 in gastric cancer cells.

Conclusions

Together, this study provided evidence that GRB7 may be an effective molecular targets for the treatment of gastric cancer.
Appendix
Available only for authorised users
Literature
1.
Shan C, Zhang Y, Hao X, Gao J, Chen X, Wang K. Biogenesis, functions and clinical significance of circRNAs in gastric cancer. Mol Cancer. 2019;18(1):136.CrossRefPubMedPubMedCentral
2.
Tani H, Saito N, Kobayashi M, Kameoka S. Clinical significance of keratinocyte growth factor and K-sam gene expression in gastric cancer. Mol Med Rep. 2013;7(5):1381–6.CrossRefPubMedPubMedCentral
3.
Wang X, Zhu G, Yang H, Gao R, Wu Z, Zhang Y, Zhu X, Zhang X, Li J. Radix Rhei Et RhizomeAn Investigation of the Antigastric Cancer Effect in Tumor Microenvironment of: A Network Pharmacology Study. Evid based complement altern med: eCAM. 2021;2021:9913952.
4.
Gong X, Zhang H. Diagnostic and prognostic values of anti-helicobacter pylori antibody combined with serum CA724, CA19-9, and CEA for young patients with early gastric cancer. J Clin Lab Anal. 2020;34(7):e23268.CrossRefPubMedPubMedCentral
5.
Abozeid M, Rosato A, Sommaggio R. Immunotherapeutic strategies for gastric carcinoma: a review of preclinical and clinical recent development. Biomed Res Int 2017, 2017:5791262.
6.
Sun J, Long Y, Peng X, Xiao D, Zhou J, Tao Y, Liu S. The survival analysis and oncogenic effects of CFP1 and 14-3-3 expression on gastric cancer. Cancer Cell Int. 2019;19:225.CrossRefPubMedPubMedCentral
7.
Patel T, Cecchini M. Targeted therapies in Advanced Gastric Cancer. Curr Treat Options Oncol. 2020;21(9):70.CrossRefPubMed
8.
Zhou F, Li N, Jiang W, Hua Z, Xia L, Wei Q, Wang L. Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial. World J Surg Oncol. 2012;10:274.CrossRefPubMedPubMedCentral
9.
Alcalde J, González-Muñoz M, Villalobo A. Grb7-derived calmodulin-binding peptides inhibit proliferation, migration and invasiveness of Tumor cells while they enhance attachment to the substrate. Heliyon. 2020;6(5):e03922.CrossRefPubMedPubMedCentral
10.
Zheng Y, Pei Y, Yang L, Zeng Z, Wang J, Xie G, Wang L, Yuan J. Upregulated GRB7 promotes proliferation and tumorigenesis of Bladder Cancer via Phospho-AKT pathway. Int J Biol Sci. 2020;16(16):3221–30.CrossRefPubMedPubMedCentral
11.
Ambaye N, Gunzburg M, Lim R, Price J, Wilce M, Wilce J. Benzopyrazine derivatives: a novel class of growth factor receptor bound protein 7 antagonists. Bioorg Med Chem. 2011;19(1):693–701.CrossRefPubMed
12.
Pero S, Daly R, Krag D. Grb7-based molecular therapeutics in cancer. Expert Rev Mol Med. 2003;5(14):1–11.CrossRefPubMed
13.
Yu C, Luo D, Yu J, Zhang M, Zheng X, Xu G, Wang J, Wang H, Xu Y, Jiang K et al. Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon Cancer. Oncogene 2021.
14.
Katoh M, Katoh M. MGC9753 gene, located within PPP1R1B-STARD3-ERBB2-GRB7 amplicon on human chromosome 17q12, encodes the seven-transmembrane receptor with extracellular six-cystein domain. Int J Oncol. 2003;22(6):1369–74.PubMed
15.
Liu H, Qin Y, Zhou N, Ma D, Wang Y. ZNF280A promotes lung adenocarcinoma development by regulating the expression of EIF3C. Cell Death Dis. 2021;12(1):39.CrossRefPubMedPubMedCentral
16.
Gaweł AM, Ratajczak M, Gajda E, Grzanka M, Paziewska A, Cieślicka M, Kulecka M, Oczko-Wojciechowska M, Godlewska M. Analysis of the role of FRMD5 in the Biology of Papillary thyroid carcinoma. Int J Mol Sci 2021, 22(13).
17.
Mejías-Luque R, Lozano-Pope I, Wanisch A, Heikenwälder M, Gerhard M, Obonyo M. Increased LIGHT expression and activation of non-canonical NF-κB are observed in gastric lesions of MyD88-deficient mice upon Helicobacter felis Infection. Sci Rep. 2019;9(1):7030.CrossRefPubMedPubMedCentral
18.
Chu P, Tai Y, Shen T. Grb7, a critical mediator of EGFR/ErbB signaling, in Cancer Development and as a potential therapeutic target. Cells 2019, 8(5).
19.
Gotovac J, Liu D, Yates M, Milne J, Macpherson A, Simpson K, Eslick G, Mitchell C, Duong C, Phillips W, et al. GRB7 is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma. J Pathol. 2020;252(3):317–29.CrossRefPubMedPubMedCentral
20.
Tang H, Yang P, Yang X, Peng S, Hu X, Bao G. Growth factor receptor bound protein-7 regulates proliferation, cell cycle, and mitochondrial apoptosis of thyroid cancer cells via MAPK/ERK signaling. Mol Cell Biochem. 2020;472:209–18.CrossRefPubMed
21.
Wang C, Yin W, Chen P. MicroRNA-374a-5p promotes metastasis of colorectal cancer by targeting GRB7. Panminerva medica. 2020.
22.
Chen K, Liu M, Mak C, Yung M, Leung T, Xu D, Ngu S, Chan K, Yang H, Ngan H, et al. miR-193a-3pMethylation-associated silencing of promotes Ovarian cancer aggressiveness by targeting GRB7 and MAPK/ERK pathways. Theranostics. 2018;8(2):423–36.CrossRefPubMedPubMedCentral
23.
Paudyal P, Shrestha S, Madanayake T, Shuster C, Rohrschneider L, Rowland A, Lyons B. Grb7 and Filamin-a associate and are colocalized to cell membrane ruffles upon EGF stimulation. J Mol Recognition: JMR. 2013;26(11):532–41.CrossRef
24.
Pero S, Oligino L, Daly R, Soden A, Liu C, Roller P, Li P, Krag D. Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7. J Biol Chem. 2002;277(14):11918–26.CrossRefPubMed
25.
de Oliveira Peixoto J, Savoldi I, Ibelli A, Cantão M, Jaenisch F, Giachetto P, Settles M, Zanella R, Marchesi J, Pandolfi J, et al. Proximal femoral head transcriptome reveals novel candidate genes related to epiphysiolysis in broiler chickens. BMC Genomics. 2019;20(1):1031.CrossRefPubMedPubMedCentral
26.
Zhou Y, Li Y, Zheng J, Liu K, Zhang H. Detecting of gastric cancer by Bcl-2 and Ki67. Int J Clin Exp Pathol. 2015;8(6):7287–90.PubMedPubMedCentral
27.
Wang Y, Chan D, Liu V, Chiu P, Ngan H. Differential functions of growth factor receptor-bound protein 7 (GRB7) and its variant GRB7v in ovarian carcinogenesis. Clin cancer Research: Official J Am Association Cancer Res. 2010;16(9):2529–39.CrossRef
28.
Lu F, Yang H, Lin SD, Zhao L, Jiang C, Chen ZB, Liu YY, Kan YJ, Hu J, Pang WS. Cyclic peptide extracts derived from Pseudostellaria heterophylla ameliorates COPD via Regulation of the TLR4/MyD88 pathway proteins. Front Pharmacol. 2020;11:850.CrossRefPubMedPubMedCentral
29.
Patra MC, Choi S. Recent progress in the Molecular Recognition and Therapeutic Importance of Interleukin-1 receptor-Associated kinase 4. Molecules 2016, 21(11).
30.
Chen J, Xia D, Xu M, Su R, Lin W, Guo D, Chen G, Liu S. Expression and significance of MyD88 in patients with gastric Cardia Cancer in a high-incidence area of China. Front Oncol. 2020;10:559.CrossRefPubMedPubMedCentral
31.
Vogelaar I, Ligtenberg M, van der Post R, de Voer R, Kets C, Jansen T, Jacobs L, Schreibelt G, de Vries I, Netea M, et al. Recurrent candidiasis and early-onset gastric cancer in a patient with a genetically defined partial MYD88 defect. Fam Cancer. 2016;15(2):289–96.CrossRefPubMed
32.
Chalmers SA, Eidelman AS, Ewer JC, Ricca JM, Serrano A, Tucker KC, Vail CM, Kurt RA. A role for HMGB1, HSP60 and Myd88 in growth of murine mammary carcinoma in vitro. Cell Immunol. 2013;282(2):136–45.CrossRefPubMedPubMedCentral
Metadata
Title
GRB7 plays a promoting role in the progression of gastric cancer
Authors
Guomin Zhu
Hu Cai
Qiang Xiao
Shukun Zeng
Xiaohua Jiang
Donglan Liu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11694-5

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Development of a sensitive droplet digital PCR according to the HPV infection specificity in Chinese population

Research

Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials

Study protocol

Comparing biweekly single-dose actinomycin D with multiday methotrexate therapy for low-risk gestational trophoblastic neoplasia (FIGO Score 0–4): study protocol for a prospective, multicentre, randomized trial

Research

Treatment compliance among adult cervical cancer patients receiving care at Uganda cancer institute, Uganda: a retrospective data review

Research

Cancer incidence and mortality in Brunei Darussalam, 2011 to 2020

Research

Advanced Ann Arbor stage and age over 60 years as prognostic predictors in patients with primary cervical lymphoma: a retrospective cohort study and systematic review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits